title: Some economic consequences of noncompliance.
abstract: The twin problems of poor compliance and poor persistence with prescribed antihypertensive drug regimens appear to be responsible for much of the huge shortfall in the proportion of hypertensives whose treatment brings their blood pressure down to satisfactory levels. A further problem is the confounding of nonresponse and poor compliance in patients with "drug-resistant hypertension," in that about half of such patients are poor compliers, whose response to simple regimens usually proves satisfactory once their compliance with prescribed regimens is corrected. Electronic means for compiling ambulatory patients' drug dosing histories have now made it both technically and economically feasible to distinguish clearly between noncompliers and nonresponders, which clinical judgment cannot do because it is no better at making this crucial distinction than a coin toss. With the advent of reliable, economical measurements of patient compliance with prescribed drug dosing regimens, we can probably eliminate most of the compliance problems. The problem awaiting us after that is poor persistence with prescribed regimens for antihypertensive and other cardiovascular medicines that are meant for long-term or life-long use. A recent study has shown that median persistence with fully reimbursed drugs of the statin class is only 6 months, which is about one fortieth of the length it should be to realize full benefits of such therapy.
authors.affiliation: urquhart@ix.netcom.com
authors.forename: J
authors.initials: J
authors.lastname: Urquhart
mesh_terms: D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000191:economics*; D016312:Treatment Refusal
chemical_list: D000959:Antihypertensive Agents